Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 09, 2023

SELL
$1.74 - $3.27 $5,568 - $10,464
-3,200 Reduced 54.24%
2,700 $5,000
Q2 2022

Aug 11, 2022

BUY
$2.04 - $4.68 $204 - $468
100 Added 1.72%
5,900 $17,000
Q1 2022

May 12, 2022

BUY
$3.52 - $5.46 $7,040 - $10,920
2,000 Added 52.63%
5,800 $24,000
Q4 2021

Feb 11, 2022

BUY
$5.1 - $7.0 $8,670 - $11,900
1,700 Added 80.95%
3,800 $20,000
Q3 2021

Nov 12, 2021

BUY
$5.32 - $7.37 $11,172 - $15,477
2,100 New
2,100 $14,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $272M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.